# Multiple sclerosis-associated uveitis successfully controlled with ofatumumab

## TL;DR

This case report shows that ofatumumab effectively controlled eye inflammation in three patients with multiple sclerosis-associated uveitis.

## Contribution

The first case report describing successful treatment of MS-associated uveitis with ofatumumab.

## Key findings

- Ofatumumab significantly improved vitreous cell and vascular leakage in a patient with occlusive retinal vasculitis.
- Switching to ofatumumab resolved uveitis and eliminated the need for corticosteroid injections in another patient.
- Ofatumumab allowed for reduced corticosteroid use in a patient with intermediate uveitis over nine months.

## Abstract

To report three cases of patients with multiple sclerosis (MS)-associated uveitis whose ocular inflammation responded well to ofatumumab.

Case 1: A 26-year-old male with bilateral MS-associated occlusive retinal vasculitis presented with 1 + vitreous cell in both eyes and diffuse vascular leakage in both eyes on fluorescein angiography (FA). After treatment with ofatumumab for 19 months, there was significant improvement in vitreous cell and vascular leakage bilaterally. Case 2: A 41-year-old male with bilateral MS-associated intermediate uveitis presented with 2 + vitreous cell bilaterally. FA demonstrated bilateral vascular leakage with cystoid macular edema. After transitioning to ofatumumab from ocrelizumab and corticosteroid injections, exam remained quiet with resolved FA leakage bilaterally without further injections for 10 months. Case 3: A 51 year old female with MS initially presented with 2 + AC cell in the left eye and was started on mycophenolate mofetil with improvement but was unable to wean off topical corticosteroids. After switching to ofatumumab, she remained quiet on prednisolone acetate once daily in both eyes for nine months.

While the benefits of ofatumumab have been well reported in MS, this is the first case report to describe the successful treatment of MS-associated uveitis with ofatumumab. Ofatumumab may prove to be an effective therapeutic option for these patients, with the additional benefit of self-administration. Further studies would be beneficial to identify the patients who would most benefit from this treatment.